Treatment of Levodopa-Induced Dyskinesias : Results of 2 Randomized Controlled Trials
暂无分享,去创建一个
Daniela Berg | Maria Stamelou | Marc Vandemeulebroecke | Karla Eggert | Alexander Storch | Heiko Huber | Baltazar Gomez-Mancilla | Fabrizio Gasparini | D. Berg | M. Stamelou | F. Gasparini | T. Di Paolo | W. Abi-Saab | C. Trenkwalder | A. Storch | V. Ries | J. Godau | H. Huber | B. Gomez-Mancilla | K. Eggert | M. Vandemeulebroecke | Claudia Trenkwalder | Jana Godau | Walid Abi-Saab | T. Paolo | Christine Schneider | Martin Wolz | Donald Johns | Vincent Ries | Thérèse Di Paolo | Iiona Csoti | Monica Morelli-Canelo | Sam Hariry | Katy Cooke | M. Wolz | C. Schneider | Donald R. Johns | S. Hariry | K. Cooke | D. Johns | Iiona Csoti | M. Morelli-Canelo | IIona Csoti
[1] T. Chase,et al. Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD , 2005, Experimental Neurology.
[2] A. Bonnet,et al. [The Unified Parkinson's Disease Rating Scale]. , 2000, Revue neurologique.
[3] P. Bédard,et al. Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. , 1993, Clinical neuropharmacology.
[4] C. Goetz,et al. Levodopa‐induced dyskinesias , 2007, Movement disorders : official journal of the Movement Disorder Society.
[5] Evaluation of dyskinesias in a pilot, randomized, placebo-controlled trial of remacemide in advanced Parkinson disease. , 2001, Archives of neurology.
[6] J. Jankovic,et al. Current approaches to the treatment of Parkinson’s disease , 2008, Neuropsychiatric disease and treatment.
[7] W. Danysz,et al. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease , 2006, Brain Research Bulletin.
[8] M. Onofrj,et al. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. , 2004, Journal of neurology, neurosurgery, and psychiatry.
[9] Y. Agid,et al. Levodopa‐induced dyskinesias in Parkinson's disease phenomenology and pathophysiology , 1994, Movement disorders : official journal of the Movement Disorder Society.
[10] A Schnitzler,et al. Review: Deep brain stimulation in Parkinson’s disease , 2009, Therapeutic advances in neurological disorders.
[11] L. Grégoire,et al. mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys , 2008, Neurobiology of Aging.
[12] W. Danysz,et al. Antagonism of metabotropic glutamate receptor type 5 attenuates l‐DOPA‐induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson’s disease , 2007, Journal of neurochemistry.
[13] G. Nappi,et al. Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease , 2008, Neurobiology of Disease.
[14] L. Grégoire,et al. Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys , 2010, Neuropharmacology.
[15] J. Brotchie,et al. Reduction of l-DOPA-Induced Dyskinesia by the Selective Metabotropic Glutamate Receptor 5 Antagonist 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease , 2010, Journal of Pharmacology and Experimental Therapeutics.
[16] S. Konitsiotis,et al. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. , 1999, Archives of neurology.
[17] T. Chase,et al. Levodopa‐induced dyskinesias improved by a glutamate antagonist in parkinsonia monkeys , 1996 .
[18] T. Chase,et al. Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism , 2000, Trends in Neurosciences.